Zhang Xiangying, Ding Jianbo, Gou Chunyan, Wen Tao, Li Li, Wang Xiaojun, Yang Huasheng, Liu Dan, Lou Jinli, Chen Dexi, Ren Feng, Li Xiuhui
Beijing You-An Hospital, Capital Medical University, Beijing 100069, PR China; Beijing Institute of Hepatology, Beijing 100069, PR China.
Beijing You-An Hospital, Capital Medical University, Beijing 100069, PR China.
J Ethnopharmacol. 2017 Apr 6;201:108-116. doi: 10.1016/j.jep.2016.11.007. Epub 2016 Nov 7.
The Qingchangligan formula, a traditional Chinese medicine comprising five herbs, is useful for treatment of patients with liver failure; however, its protective and regulatory mechanisms remain elusive.
To test the hypothesis that the Qingchangligan formula protects mice against acute liver failure by inhibiting liver inflammation.
Acute liver failure (ALF) was induced by intraperitoneal injection of D-GalN (700mg/kg) plus LPS (10μg/kg). The Qingchangligan formula was administered to mice in three doses of 50mg/kg (on day 1, day 2, and day 3) prior to D-GalN/LPS injection by intragastric administration. The mice in different groups were sacrificed at 6h after D-GalN/LPS injection, and liver samples and blood were collected for analysis.
Administration of the Qingchangligan formula not only ameliorated liver injury, as evidenced by reduced transaminase levels and well-preserved liver architecture, but also decreased the lethality in ALF mice. Moreover, in the ALF model, pretreatment with the Qingchangligan formula alleviated liver inflammation and decreased hepatocyte apoptosis. Further demonstrating the protective effects of the Qingchangligan formula, we found that pretreatment with the Qingchangligan formula reduced the expression of inflammatory cytokines by decreasing the expression of components of the mitogen-activated protein kinase (MAPK) pathway and promoting autophagy in vitro and in vivo.
Our findings demonstrated that the Qingchangligan formula exerts a protective effect against the pathophysiology of ALF, especially in regulating liver inflammation, and provide a rationale for using the Qingchangligan formula as a potential therapeutic strategy to ameliorate ALF.
清肠利胆方是一种由五味草药组成的中药,对肝功能衰竭患者的治疗有效;然而,其保护和调节机制仍不清楚。
验证清肠利胆方通过抑制肝脏炎症保护小鼠免受急性肝功能衰竭的假说。
通过腹腔注射D-半乳糖胺(700mg/kg)加脂多糖(10μg/kg)诱导急性肝功能衰竭(ALF)。在注射D-半乳糖胺/脂多糖之前,通过灌胃给药,以50mg/kg的三种剂量(第1天、第2天和第3天)给小鼠施用清肠利胆方。在注射D-半乳糖胺/脂多糖后6小时处死不同组的小鼠,收集肝脏样本和血液进行分析。
施用清肠利胆方不仅改善了肝损伤,这通过转氨酶水平降低和肝脏结构保存良好得到证明,而且还降低了ALF小鼠的致死率。此外,在ALF模型中,用清肠利胆方预处理减轻了肝脏炎症并减少了肝细胞凋亡。进一步证明清肠利胆方的保护作用,我们发现用清肠利胆方预处理通过降低丝裂原活化蛋白激酶(MAPK)途径成分的表达并在体外和体内促进自噬来降低炎性细胞因子的表达。
我们的研究结果表明,清肠利胆方对ALF的病理生理学具有保护作用,特别是在调节肝脏炎症方面,并为使用清肠利胆方作为改善ALF的潜在治疗策略提供了理论依据。